Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple
dose levels of ESK-001 compared with placebo in adult patients with SLE.